Latest news with #Emcure
Time of India
6 days ago
- Business
- Time of India
Emcure, Sanofi tie up for anti-diabetic range
New Delhi: Emcure Pharma and Sanofi India announced that they entered into an exclusive distribution and promotion agreement for the latter's oral anti-diabetic products in India, effective immediately. Emcure will exclusively distribute and promote the range of products, which include brands like Amaryl and Cetapin.
&w=3840&q=100)
Business Standard
6 days ago
- Business
- Business Standard
Emcure enters distribution agreement with Sanofi for diabetes drugs
Emcure to distribute and promote Sanofi's oral anti-diabetic brands Amaryl and Cetapin in India, expanding access amid rising prevalence of uncontrolled diabetes Emcure added that it will engage with healthcare professionals and expand the reach of these therapeutic solutions for patients across the country. Sanket Koul New Delhi Pune-based Emcure Pharmaceuticals on Wednesday announced an exclusive distribution and promotion agreement with Sanofi India (SIL) for its oral anti-diabetic (OAD) products in India. Under the agreement, SIL will continue to own and manufacture the brands across its plants in India and internationally, while Emcure will exclusively distribute and promote SIL's OAD range, which includes well-established brands such as Amaryl and Cetapin. There will be no employee transition from SIL to Emcure as part of this arrangement, the Pune-based drugmaker said in a regulatory filing to the exchanges. Emcure added that it will engage with healthcare professionals and expand the reach of these therapeutic solutions for patients across the country. 'With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them,' he added. Over 100 million Indians are currently living with type 2 diabetes and its associated complications, according to a study by the Indian Council of Medical Research–INDIAB (India Diabetes). 'Of these, more than 60 per cent are living with uncontrolled blood sugar levels and are at higher risk of developing complications over time,' said Eric Mansion, general manager (pharma) for Southeast Asia and India at Sanofi. He added that with Emcure's wide and deeply penetrated presence across India, the company is confident of tapping the full growth potential of Amaryl and Cetapin. The announcement was made post market hours. On Wednesday, shares of Emcure Pharmaceuticals closed marginally higher by 0.22 per cent at Rs 1,363.85 apiece on the Bombay Stock Exchange (BSE).
Business Upturn
7 days ago
- Business
- Business Upturn
Emcure and Sanofi India announce exclusive partnership to distribute oral anti-diabetic drugs in India
By Aditya Bhagchandani Published on July 16, 2025, 17:23 IST Emcure Pharmaceuticals Ltd. and Sanofi India Ltd. (SIL) have announced an exclusive distribution and promotion agreement for Sanofi's oral anti-diabetic (OAD) products in India, effective immediately. Under this partnership, Emcure will distribute and promote SIL's widely prescribed OAD brands, including Amaryl® and Cetapin®, leveraging its deep reach and network across India. Sanofi will continue to own and manufacture these products at its plants in India and globally. The collaboration aims to expand access to trusted oral diabetes medicines to millions of patients across the country. Notably, there will be no employee transfers from Sanofi to Emcure as part of this deal. Eric Mansion, GM Pharma Southeast Asia and India at Sanofi, said: 'Over 100 million Indians live with type 2 diabetes, and more than 60% have uncontrolled blood sugar levels. With Emcure's reach, we aim to unlock the full potential of our industry-leading OADs for patients and healthcare professionals.' Satish Mehta, CEO & MD of Emcure, added: 'This partnership aligns with our mission to improve patient access to high-quality therapies and complements our existing diabetes portfolio, supporting better diabetes care nationwide.' This alliance brings together Sanofi's strong brand portfolio and Emcure's extensive distribution network, strengthening both companies' presence in the critical diabetes care segment. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Standard
7 days ago
- Business
- Business Standard
Emcure Pharmaceuticals signs exclusive agreement with Sanofi India
To distribute and promote Emcure's oral anti-diabetic (OAD) products in India Emcure Pharmaceuticals (Emcure) and Sanofi India (SIL) today entered into an exclusive distribution and promotion agreement for SIL's oral anti-diabetic (OAD) products in India, effective immediately. Emcure will exclusively distribute and promote the Company's OAD range of products that include well-established brands like Amaryl and Cetapin. While SIL will continue to own and manufacture these brands across Sanofi's plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all of India. There will be no people transition from SIL to Emcure in this arrangement.
Time of India
7 days ago
- Business
- Time of India
Emcure, Sanofi ink distribution pact for oral anti-diabetic products in India
Emcure Pharmaceuticals Ltd and Sanofi India Ltd on Wednesday said they have entered into an exclusive distribution and promotion agreement for the latter's oral anti-diabetic products in India with immediate effect. Under the agreement, Emcure will exclusively distribute and promote Sanofi India's OAD (oral anti-diabetic) range of products that include brands like Amaryl and Cetapin, the two companies said in a joint statement. Explore courses from Top Institutes in Select a Course Category Operations Management Data Analytics Finance Data Science Artificial Intelligence MBA Product Management PGDM Technology Project Management Healthcare Cybersecurity Public Policy Degree MCA Leadership Management CXO Others Digital Marketing healthcare others Design Thinking Data Science Skills you'll gain: Quality Management & Lean Six Sigma Analytical Tools Supply Chain Management & Strategies Service Operations Management Duration: 10 Months IIM Lucknow IIML Executive Programme in Strategic Operations Management & Supply Chain Analytics Starts on Jan 27, 2024 Get Details Sanofi India will continue to own and manufacture these brands across its plants in India and internationally, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Hörspezialisten verlieren Kunden: Dieses 89€-Gerät spricht sich herum Top Trending News Today Mehr erfahren Undo "With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them," Emcure Pharmaceuticals CEO and MD Satish Mehta said. Further, he said, "This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country." Live Events Similarly, Sanofi General Manager Pharma Southeast Asia and India & MCO Lead, Eric Mansion, said, "With Emcure's wide and deeply penetrated presence across India, we are confident of tapping into the full growth potential of our best-in-class and industry-leading OADs Amaryl and Cetapin. This partnership will truly benefit both - the patients who need them and the healthcare professionals who trust and prescribe them." The two companies said there would be no people transition from Sanofi India to Emcure under their distribution and promotion agreement.
